INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 222 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,631 | -76.8% | 94,204 | -73.3% | 0.00% | – |
| Q2 2023 | $157,817 | -5.5% | 352,174 | +72.2% | 0.00% | – |
| Q1 2023 | $167,054 | -33.4% | 204,503 | +27.1% | 0.00% | -100.0% |
| Q4 2022 | $251,000 | -14.6% | 160,869 | -5.9% | 0.00% | 0.0% |
| Q3 2022 | $294,000 | -5.5% | 170,875 | -4.8% | 0.00% | 0.0% |
| Q2 2022 | $311,000 | -50.4% | 179,478 | +14.1% | 0.00% | 0.0% |
| Q1 2022 | $627,000 | -6.1% | 157,239 | +17.9% | 0.00% | 0.0% |
| Q4 2021 | $668,000 | -52.3% | 133,376 | -32.0% | 0.00% | -66.7% |
| Q3 2021 | $1,401,000 | -2.6% | 196,018 | +26.4% | 0.00% | 0.0% |
| Q2 2021 | $1,439,000 | +8.4% | 155,076 | +8.5% | 0.00% | 0.0% |
| Q1 2021 | $1,327,000 | +2.3% | 142,904 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $1,297,000 | -49.9% | 146,460 | -32.5% | 0.00% | -62.5% |
| Q3 2020 | $2,589,000 | -28.8% | 217,003 | +60.9% | 0.01% | -33.3% |
| Q2 2020 | $3,637,000 | +768.0% | 134,878 | +142.6% | 0.01% | +500.0% |
| Q1 2020 | $419,000 | – | 55,603 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |